Ask AI
ProCE Banner Activity

Updates on New Treatment Options for Previously Treated MM: Optimizing Therapy Sequencing in R/R MM

Slideset

Downloadable slides on evidence-based approaches guiding the optimal selection and sequencing of treatments for patients with relapsed/refractory multiple myeloma.

Released: May 29, 2026

Continue Activity

Share

Provided by

Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Decera Clinical Education.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Johnson & Johnson.
This educational activity is supported by an independent medical education grant from GSK.

AstraZeneca

GSK

Johnson & Johnson

Partners

Decera Clinical Education

ProCE Banner

Target Audience

This activity is intended for hematologists, oncologists, advance practice providers, nurses, pharmacists, and other healthcare professionals who care for patients with multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Initiate timely systemic treatment for appropriate patients based on risk assessment and the latest multiple myeloma diagnostic and staging criteria

  • Develop individualized treatment strategies for patients with newly diagnosed multiple myeloma through consideration of the available clinical data as well as NCCN Guidelines, risk assessment, comorbidities, and patient age/fitness and preferences

  • Select optimal sequencing and bridging therapies for patients with relapsed/refractory multiple myeloma based on individual patient and disease characteristics, as well as NCCN Guideline recommendations and response to and tolerance of previous therapies

  • Appraise the latest clinical data for current and emerging therapies/regimens for patients with multiple myeloma

  • Implement strategies to improve access, quality of care, and equitable clinical trial enrollment for all patients with multiple myeloma